Patients with IDH-mutant, grade 3 astrocytoma showed clinically meaningful improvements in OS, PFS<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Dec. 16, 2025 (HealthDay News) — For patients with recurrent grade 3 astrocytoma, clinically meaningful improvements were seen for eflornithine + lomustine versus lomustine monotherapy, according to a study published online Dec. 1 in the Journal of Clinical Oncology<\/em>.<\/p>\n Howard Colman, M.D., Ph.D., from the University of Utah in Salt Lake City, and colleagues conducted a randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. A total of 343 patients from 74 sites in eight countries were randomly assigned to eflornithine (2.8 g\/m2<\/sup> orally, every eight hours [two weeks on, one week off]) + lomustine (90 mg\/m2<\/sup> orally, once every six weeks), or lomustine monotherapy (110 mg\/m2<\/sup> once every six weeks).<\/p>\n The researchers found no difference in survival between the eflornithine + lomustine and lomustine monotherapy groups (mean overall survival, 23.4 versus 20.3 months; hazard ratio, 0.94). In a subset analysis of 196 patients with IDH<\/em>-mutant grade 3 astrocytoma, clinically meaningful improvements were seen in median overall survival (34.9 versus 23.5 months; hazard ratio, 0.64) and median progression-free survival (15.8 versus 7.2 months; hazard ratio, 0.57) with eflornithine + lomustine versus lomustine monotherapy. For patients with central nervous system grade 4 disease, no differences were observed.<\/p>\n “It’s incredibly rewarding to be involved in a study like STELLAR, which demonstrated a combination treatment that has a significant benefit and offers incredible potential for patients with this specific diagnosis,” Colman said in a statement.<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n